2,4-Dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine

Catalog No. :
ACRNUS356
CAS No. :
1951411-46-3
Molecular Formula :
C12H19BN2O2
Molecular Weight :
234.11

IUPAC Name:2,4-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine

2,4-Dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g98%$1170.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2,4-Dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine
IUPAC Name2,4-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine
MDL No.MFCD21099682
Molecular FormulaC12H19BN2O2
Molecular Weight234.11
SMILESCC1(OB(C2C(C)=NC(C)=NC=2)OC1(C)C)C
InChI KeyJFMTXZKAWSJUFL-UHFFFAOYSA-N
Synonym2,4-Dimethyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyrimidine;Pyrimidine, 2,4-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
CAS No.1951411-46-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACRNUS356 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. ACXGPU241 route compound structure diagram
    ACXGPU24169696-37-3 In Stock
  4. Then
  5. ACRNUS356 route product structure diagram
    ACRNUS3561951411-46-3
Inquiry

2. ACRNUS356 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRNUS356 route product structure diagram
    ACRNUS3561951411-46-3
Inquiry

Comments (0)